REG - Oxford BioDynamics - Grant of Options

Oxford BiodynamicsAnnouncement

21/06/2024 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240621:nRSU4578Ta&default-theme=true

RNS Number : 4578T  Oxford BioDynamics PLC  21 June 2024

 

 

 Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing / Grant of Share Options

 

21 June 2024 - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
developing precision medicine tests based on the EpiSwitch® 3D genomics
platform, announces that it has granted a total of 10,665,020 options over its
ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group
employees, including 10,150,020 options to Chief Executive Officer, Dr Jon
Burrows ("the Grant of Options"). The options were granted under the Company's
2016 Employee Share Option Plan with an exercise price of 9p per share.

 

One-third of the options granted to Dr Burrows will vest and become
exercisable on each of 23 March 2025, 23 March 2026 and 23 March 2027. Vested
options will remain exercisable up to and including the tenth anniversary of
the date of grant.

 

Following this grant, Dr Jon Burrows, holds options over Ordinary Shares and
is interested in Ordinary Shares as follows:

 

              Total number of options over Ordinary Shares  Ordinary Shares held
              Number                                                     % of current issued share capital
 Jon Burrows  12,773,734                                    1,088,888    0.35%

 

The Grant of Options constitutes a related party transaction pursuant to AIM
Rule 13. The independent directors of the Company consider, having consulted
with the Company's nominated adviser, Shore Capital and Corporate Limited,
that the Grant of Options is fair and reasonable insofar as the Company's
shareholders are concerned.

 

The information set out below is provided in accordance with the requirements
of the UK Market Abuse Regulation.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Jon Burrows
 2   Reason for the notification
 a)  Position/status                                              Director/PDMR
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Oxford BioDynamics Plc
 b)  LEI                                                          2138005Y1TK258O5U928
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 1 pence each

     Identification code

                                                                  ISIN:   GB00BD5H8572
 b)  Nature of the transaction                                    Grant of share options
 c)  Price(s) and volume(s)                                       10,150,020 Ordinary Shares at an exercise price of 9 pence per share

 d)  Aggregated information                                       N/A

     - Aggregated volume

     - Price

 e)  Date of the transaction                                      21 June 2024

 f)  Place of the transaction                                     Outside a trading venue

 

 

For further details please contact:

 Oxford BioDynamics Plc                                Tel: +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                                         Tel: +44 (0)20 7408 4090

 Nominated Adviser and Broker

 Stephane Auton / Lucy Bowden

 Instinctif Partners

 Melanie Toyne-Sewell / Katie Duffell / Jack Kincade   Tel: +44 (0)20 7457 2020

                                                       OxfordBioDynamics@instinctif.com (mailto:OxfordBioDynamics@instinctif.com)

 

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

It has two commercially available products: the EpiSwitch® PSE
(http://www.94percent.com/)  (EpiSwitch Prostate Screening test)
and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE is a blood test that
boosts the predictive accuracy of a PSA test from 55% to 94% when testing the
presence or absence of prostate cancer, which has been launched in the US
and UK in September 2023. CiRT is a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in February
2022.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring, in a wide range of
indications, including oncology, neurology, inflammation, hepatology and
animal health.

In March 2021, the Company launched the first commercially available
microarray kit for high-resolution 3D genome profiling and biomarker
discovery, the EpiSwitch Explorer Array Kit
(https://store.oxfordbiodynamics.com/) which is available for purchase by the
life science research community.

OBD has participated in more than 40 partnerships with big pharma and leading
institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo
Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD's group headquarters and research, product development and UK clinical
laboratories are in Oxford, UK. It also has a commercial office
in Gaithersburg, MD, USA and a clinical laboratory in Frederick, MD, USA,
and a reference laboratory in Penang, Malaysia.

The company is listed on the London Stock Exchange's AIM, with ticker OBD. For
more information, please visit the Company's
website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on X
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHZFLFLZQLLBBQ